| A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (NCT05998941) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-01 |
| A Study of TQB3454 Tablets in Patients With Blood Tumors (NCT06218771) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-07-10 |
| A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection (NCT06198764) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-07-06 |
| Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma (NCT05830500) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-06-19 |
| A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis (NCT05970432) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-06-19 |
| Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging (NCT05687864) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-06-17 |
| A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer (NCT05913089) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-06-14 |
| Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. (NCT05922345) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-06-08 |
| TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers (NCT05894421) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-06-06 |
| To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. (NCT05859373) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-06-01 |
| Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT05834543) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-05-26 |
| A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma (NCT05783921) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-05-23 |
| Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. (NCT05862337) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-05-10 |
| A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (NCT06202261) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-04-13 |
| Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer (NCT05780567) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-03-30 |
| Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State (NCT06768619) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-03-20 |
| A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects (NCT05646758) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-03-17 |
| A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer (NCT05775575) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-03-02 |
| Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer (NCT05745363) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-02-24 |
| Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer (NCT05815862) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-02-15 |
| TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. (NCT05718167) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-02-01 |
| Material Balance Study of TQ-B3525 (NCT05675202) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-01-01 |
| A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test (NCT05634473) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-12-01 |
| Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects (NCT05610202) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-11-01 |
| TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-10-27 |
| Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients (NCT05559242) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-10-01 |
| Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. (NCT05472324) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-09-23 |
| To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis (NCT05607446) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-09-14 |
| A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors (NCT06116240) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-09-02 |
| Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (NCT05481645) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-08-26 |
| To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer (NCT05405439) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-08-25 |
| Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma (NCT05451407) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-08-09 |
| TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma (NCT05496569) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-08-08 |
| TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients (NCT06388759) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-08-01 |
| Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers (NCT05333276) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-07-29 |
| To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (NCT05365178) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-07-01 |
| A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (NCT04941404) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-06-10 |
| To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma (NCT05400876) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-06-09 |
| Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers (NCT05353179) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-06-01 |
| Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors (NCT05416359) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-06-01 |
| A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects (NCT05380934) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-05-29 |
| A Phase II Clinical Trial of TQC3721 Suspension for Inhalation (NCT05292196) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-05-20 |
| Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes (NCT05426798) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-04-29 |
| Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor (NCT05487976) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-04-28 |
| Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors (NCT05645315) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-04-28 |
| To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects (NCT05340530) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-04-01 |
| TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail (NCT05375461) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-03-18 |
| TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer (NCT05284994) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-03-11 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma (NCT05121350) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-03-01 |
| A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors (NCT04975204) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-02-18 |
| A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). (NCT05346952) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-01-25 |
| Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors (NCT05154630) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-01-14 |
| A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors (NCT05110807) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-01-05 |
| To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer (NCT05198531) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-01-01 |
| A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy (NCT05068921) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-12-09 |
| A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma (NCT05121363) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-12-01 |
| A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors (NCT05046847) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-11-30 |
| A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis (NCT05020652) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-11-11 |
| Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients (NCT06051565) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-11-06 |
| A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis (NCT05107037) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-11-01 |
| A Clinical Trial of TQC3721 Suspension for Inhalation (NCT05051930) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-10-18 |
| A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx (NCT05068206) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-10-08 |
| Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets (NCT06431438) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-10-01 |
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer (NCT05145218) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-09-28 |
| A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor (NCT05021367) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-09-23 |
| A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (NCT05011019) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-09-07 |
| A Study of TQB3820 in Patients With Hematological Malignancies (NCT05020639) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-08-31 |
| A Clinical Study of TQB3824 in Subjects With Advanced Cancer (NCT05028218) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-08-31 |
| A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer (NCT04924192) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-08-18 |
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) (NCT04964479) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-08-06 |
| Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers (NCT04854681) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-08-01 |
| A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes (NCT04955834) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-07-27 |
| Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC) (NCT04956328) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-07-22 |
| To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects (NCT05982106) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-07-19 |
| Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects (NCT05344729) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-07-06 |
| A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (NCT04944043) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-25 |
| Phase I Clinical Trial of TQC2731 Injection (NCT04923607) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-25 |
| A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma (NCT04895345) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-15 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets (NCT04853498) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-09 |
| A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT04808570) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-05 |
| A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer (NCT04854668) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-05-27 |
| A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects (NCT04804904) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-05-20 |
| Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle (NCT06010537) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-04-28 |
| A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors (NCT04836663) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-04-23 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors (NCT04805060) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-04-23 |
| A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma (NCT04827004) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-04-01 |
| Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules (NCT04675060) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-02-23 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer (NCT04809142) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-02-04 |
| A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer (NCT04796623) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-02-04 |
| A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） (NCT04610970) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-01-20 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors (NCT04623892) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-12-01 |
| Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. (NCT04768699) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-12-01 |
| A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） (NCT04615468) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-12-01 |
| A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer (NCT04623333) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-11-30 |
| A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics (NCT04523285) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-10-26 |
| Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. (NCT05985187) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-10-20 |
| A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies (NCT04412577) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-10-12 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer (NCT04574284) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-09-29 |
| A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics (NCT03754244) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-09-24 |
| A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis (NCT04325776) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-09-24 |